Arbaclofen Placarbil ( DrugBank: Arbaclofen, Arbaclofen Placarbil )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	2

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01360489 (ClinicalTrials.gov)	September 2011	23/5/2011	Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)	An Open Label, 26-Week Study Assessing Arbaclofen Placarbil Safety and Efficacy in Subjects With Spasticity Associated With Multiple Sclerosis With an Addendum Open-Label, 36-Week Study Assessing Arbaclofen Placarbil Safety in Subjects With Spasticity Associated With Multiple Sclerosis	Multiple Sclerosis	Drug: arbaclofen placarbil	XenoPort, Inc.	NULL	Completed	18 Years	70 Years	Both	218	Phase 3	United States
2	NCT01359566 (ClinicalTrials.gov)	May 2011	22/5/2011	Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis	A Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis	Multiple Sclerosis	Drug: Arbaclofen placarbil 15 mg BID;Drug: Placebo;Drug: Arbaclofen placarbil 30 mg BID;Drug: Arbaclofen placarbil 45 mg BID	XenoPort, Inc.	NULL	Completed	18 Years	70 Years	All	228	Phase 3	United States